NASDAQ:BGMS Cyclacel Pharmaceuticals Q4 2025 Earnings Report $0.88 0.00 (0.00%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$0.87 -0.01 (-1.36%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cyclacel Pharmaceuticals EPS ResultsActual EPS-$2.21Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACyclacel Pharmaceuticals Revenue ResultsActual Revenue$0.67 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACyclacel Pharmaceuticals Announcement DetailsQuarterQ4 2025Date3/30/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Cyclacel Pharmaceuticals Earnings HeadlinesBoise Cascade (NYSE:BCC) vs. Cyclacel Pharmaceuticals (NASDAQ:BGMS) Head to Head SurveyOctober 1, 2026 | americanbankingnews.com$HAREHOLDER ALERT - The M&A Class Action Firm Continues to Investigate the Merger— ATKR, BZH, BGMS and CBANSeptember 30, 2026 | globenewswire.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 5 at 1:00 AM | Chaikin Analytics (Ad)Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Sees Large Growth in Short InterestSeptember 27, 2026 | americanbankingnews.comEQUITY ALERT: The M&A Class Action Firm Launches Inquiry for the Merger— ATKR, BGMS, BOW and FTHMSeptember 8, 2026 | globenewswire.comBIO GREEN MED SOLUTION REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATEAugust 12, 2026 | globenewswire.comSee More Cyclacel Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cyclacel Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclacel Pharmaceuticals and other key companies, straight to your email. Email Address About Cyclacel PharmaceuticalsCyclacel Pharmaceuticals (NASDAQ:BGMS) is a clinical-stage biopharmaceutical company focused on developing targeted medicines for the treatment of cancer. The company’s research programs are designed to address molecular pathways involved in tumor growth and survival, with an emphasis on therapies for patients with limited treatment options. Cyclacel’s pipeline has included fadraciclib, an oral cyclin-dependent kinase inhibitor designed to target CDK2 and CDK9, and sapacitabine, an oral nucleoside analogue investigated for certain hematologic malignancies and solid tumors. The company has also pursued additional oncology programs involving cell-cycle regulation and other cancer-related targets. Cyclacel was founded in the United Kingdom and has conducted research and clinical development activities internationally. The company has been led by Chief Executive Officer Spiro Rombotis. Cyclacel Pharmaceuticals has historically traded under the Nasdaq symbol CYCC; the symbol provided, BGMS, could not be independently verified as the company’s current trading symbol.View Cyclacel Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the Test Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
